Design Therapeutics Management
Management criteria checks 2/4
Design Therapeutics' CEO is Pratik Shah, appointed in Aug 2023, has a tenure of 1.33 years. total yearly compensation is $6.32M, comprised of 5.7% salary and 94.3% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth $843.20K. The average tenure of the management team and the board of directors is 3.3 years and 4.1 years respectively.
Key information
Pratik Shah
Chief executive officer
US$6.3m
Total compensation
| CEO salary percentage | 5.7% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.3yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Oct 04
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Jun 19Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Mar 15Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Nov 16Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Jun 06Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Feb 09Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Oct 25Design Therapeutics GAAP EPS of -$0.27 misses by $0.02
Aug 08We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate
Jul 02Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Mar 18Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Dec 03Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Aug 18Design Therapeutics expands board of directors
Jun 07Design Therapeutics EPS misses by $0.24
May 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$48m |
| Jun 30 2024 | n/a | n/a | -US$51m |
| Mar 31 2024 | n/a | n/a | -US$59m |
| Dec 31 2023 | US$6m | US$361k | -US$67m |
| Sep 30 2023 | n/a | n/a | -US$72m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$69m |
| Dec 31 2022 | US$5m | US$338k | -US$63m |
| Sep 30 2022 | n/a | n/a | -US$57m |
| Jun 30 2022 | n/a | n/a | -US$51m |
| Mar 31 2022 | n/a | n/a | -US$43m |
| Dec 31 2021 | US$585k | US$310k | -US$36m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$19m |
| Mar 31 2021 | n/a | n/a | -US$13m |
| Dec 31 2020 | US$400k | US$250k | -US$8m |
Compensation vs Market: Pratik's total compensation ($USD6.32M) is above average for companies of similar size in the US market ($USD2.15M).
Compensation vs Earnings: Pratik's compensation has increased whilst the company is unprofitable.
CEO
Pratik Shah (54 yo)
1.3yrs
Tenure
US$6,317,780
Compensation
Dr. Pratik Shah, Ph D., is an Executive Chairperson at Design Therapeutics, Inc. since December 2017 and serves as its President, Chief Executive Officer and Principal Financial Officer since August 25, 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 1.3yrs | US$6.32m | 0.23% $ 843.2k | |
| Chief Operating Officer | 3.9yrs | US$1.28m | 1.44% $ 5.3m | |
| Co-Founder & Scientific Advisor | no data | no data | 13.54% $ 49.8m | |
| Chief Accounting Officer | 3.3yrs | no data | no data | |
| General Counsel | no data | no data | no data | |
| Consulting Chief Medical Officer | 2.9yrs | no data | 0.0084% $ 30.9k | |
| Controller | 4.7yrs | no data | no data |
3.3yrs
Average Tenure
54yo
Average Age
Experienced Management: DSGN's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7yrs | US$6.32m | 0.23% $ 843.2k | |
| Co-Founder & Scientific Advisor | no data | no data | 13.54% $ 49.8m | |
| Independent Director | 4.1yrs | US$106.70k | 0.10% $ 374.1k | |
| Independent Director | 5.4yrs | US$228.56k | 0.23% $ 863.3k | |
| Lead Independent Director | 4.8yrs | US$95.70k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$94.20k | 0.035% $ 129.8k | |
| Independent Director | 3.5yrs | US$94.20k | 0.0023% $ 8.5k | |
| Independent Director | 3.9yrs | US$104.20k | 0% $ 0 |
4.1yrs
Average Tenure
49yo
Average Age
Experienced Board: DSGN's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 07:34 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Design Therapeutics, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Goldman Sachs |
| Joseph Schwartz | Leerink Partners LLC |
| Yasmeen Rahimi | Piper Sandler Companies |